# Adolescent self-administration of the synthetic cannabinoid receptor agonist JWH-018 induces neurobiological and behavioral alterations in adult male mice

Giulia Margiani, Maria Paola Castelli, Nicholas Pintori, Roberto Frau, Maria Grazia Ennas, Valeria Orru, Valentina Serra, Edoardo Fiorillo, Paola Fadda, Giovanni Marsicano, et al.

► To cite this version:

Giulia Margiani, Maria Paola Castelli, Nicholas Pintori, Roberto Frau, Maria Grazia Ennas, et al. Adolescent self-administration of the synthetic cannabinoid receptor agonist JWH-018 induces neurobiological and behavioral alterations in adult male mice. Psychopharmacology, 2022, 239 (10), pp.3083-3102. 10.1007/s00213-022-06191-9. hal-03842334

HAL Id: hal-03842334

https://hal.science/hal-03842334

Submitted on 7 Nov 2022

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Adolescent self-administration of the synthetic cannabinoid receptor agonist JWH-018 induces neurobiological and behavioral alterations in adult male mice

Giulia Margiani<fnref n="1" /> · Maria Paola Castelli<fnref n="1" /> · Nicholas Pintori<fnref n="1" /> · Roberto Frau<fnref n="1" />,<fnref n="2" /> · Maria Grazia Ennas<fnref n="1" /> · Valeria Orrù<fnref n="3" /> · Valentina Serra<fnref n="3" /> · Edoardo Fiorillo<fnref n="3" /> · Paola Fadda<fnref n="1" />,<fnref n="6" /> · Giovanni Marsicano<fnref n="4" />,<fnref n="5" /> · Maria Antonietta De Luca<fnref n="1" />

Received: 17 January 2022 / Accepted: 10 July 2022 / Published online: 9 August 2022
© The Author(s) 2022

## Abstract

**Rationale** The use of synthetic cannabinoid receptor agonists (SCRAs) is growing among adolescents, posing major medical and psychiatric risks. JWH-018 represents the reference compound of SCRA-containing products.

**Objectives** This study was performed to evaluate the enduring consequences of adolescent voluntary consumption of JWH-018.

**Methods** The reinforcing properties of JWH-018 were characterized in male CD1 adolescent mice by intravenous self-administration (IVSA). Afterwards, behavioral, neurochemical, and molecular evaluations were performed at adulthood.

**Results** Adolescent mice acquired operant behavior (lever pressing, Fixed Ratio 1–3; 7.5 µg/kg/inf); this behavior was specifically directed at obtaining JWH-018 since it increased under Progressive Ratio schedule of reinforcement, and was absent in vehicle mice. JWH-018 IVSA was reduced by pretreatment of the CB1-antagonist/inverse agonist AM251. Adolescent exposure to JWH-018 by IVSA increased, at adulthood, both nestlet shredding and marble burying phenotypes, suggesting long-lasting repetitive/compulsive-like behavioral effects. JWH-018 did not affect risk proclivity in the wire-beam bridge task. In adult brains, there was an increase of ionized calcium binding adaptor molecule 1 (IBA-1) positive cells in the caudate-putamen (CPu) and nucleus accumbens (NAc), along with a decrease of glial fibrillary acidic protein (GFAP) immunoreactivity in the CPu. These glial alterations in adult brains were coupled with an increase of the chemokine RANTES and a decrease of the cytokines IL2 and IL13 in the cortex, and an increase of the chemokine MPC1 in the striatum.

**Conclusions** This study suggests for the first time that male mice self-administer the prototypical SCRA JWH-018 during adolescence. The adolescent voluntary consumption of JWH-018 leads to long-lasting behavioral and neurochemical aberrations along with glia-mediated inflammatory responses in adult brains.

**Keywords** Synthetic cannabinoid receptor agonist · Neuroinflammation · GFAP · IBA-1 · Cytokines · Chemokines

Giulia Margiani and Maria Paola Castelli equal contribution.

<figure><img src="image_2.png" /></figure>

## Introduction

Adolescence is a critical period in brain development and maturation (Schneider 2013; Manitt et al. 2010; Naneix et al. 2012); this phase of life is an at-risk period for substance use and exposure to drugs, including cannabinoids (Hurd et al. 2014). Therefore, drug abuse propensity during adolescence is higher than in adulthood due to many factors, such as novelty-seeking behavior (Chambers et al. 2003), and a higher sensitivity to the rewarding effects of drugs of abuse (Spear 2016).

The endocannabinoid system, including arachidonoyl ethanol amide (anandamide/AEA), 2-arachidonoylglycerol (2-AG), and cannabinoid receptor 1 (CB1R), achieves

<footnote>Maria Antonietta De Luca
deluca@unica.it</footnote>

<footnote n="1">¹ Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy</footnote>

<footnote n="2">² “Guy Everett” Laboratory, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy</footnote>

<footnote n="3">³ Institute for Genetic and Biomedical Research, National Research Council (CNR), Lanusei, Italy</footnote>

<footnote n="4">⁴ INSERM, U1215 NeuroCentre Magendie, Bordeaux, France</footnote>

<footnote n="5">⁵ University of Bordeaux, Bordeaux, France</footnote>

<footnote n="6">⁶ Institute of Neuroscience-Cagliari, National Research Council (CNR), Cagliari, Italy</footnote>
maximum expression during adolescence with a subsequent decline at adulthood (Glass et al. 1997; Meyer et al. 2018); this system plays an important role in cognitive and rewarding functions (Koob and Volkow 2010; Parsons and Hurd 2015). Indeed, the EC system modulates dopamine (DA) response to natural reward, as it finely controls the activity of DAergic projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc), modulating rewarding and reinforcing behaviors (De Luca et al. 2014) and, ultimately, affecting drug use and abuse (Parsons and Hurd 2015).

Synthetic cannabinoid receptor agonists (SCRAs) are the most used novel psychoactive substances (NPS) (Pintori et al. 2017; Miliano et al. 2018; EMCDDA 2019; Musa et al. 2020), particularly among adolescents (Ninnemann et al. 2017), and are posing significant medical and psychiatric risks worldwide (Palamar et al. 2017). Compared to Δ9-tetrahydrocannabinol (THC), the principal psychoactive constituent of Cannabis, SCRAs are extremely potent full agonists of brain CBRs (De Luca et al. 2016), inducing longer-lasting and more adverse effects than Cannabis (Atwood et al. 2010; Cohen and Weinstein 2018). The SCRA JWH-018 (1-pentyl-3-(1-naphthoyl) indole) shares with other drugs of abuse (i.e., ethanol, heroin, cocaine) the ability to stimulate DA release in the NAc shell compared to other DAergic terminal areas arising from VTA (e.g., PFC, NAc core) (Di Chiara 2002, 2004). Recently, in adult rats, we showed that repeated JWH-018 exposure elicits anxious and aversive behaviors, transitory attentional deficits, withdrawal signs, and modifies basal and stimulated DAergic transmission (Pintori et al. 2021). Consistently, SCRA users frequently report adverse effects such as repetitive and compulsive-like behaviors, altered emotional states (Angoa-Pérez et al. 2013), and a propensity for risk-taking behaviors (Clayton et al. 2017).

Glial cells are actively involved in many aspects of central nervous system physiological functions (Araque et al. 2014; Salter and Beggs 2014). They are affected by exposure to different classes of drugs of abuse (Lacagnina et al. 2017; Linker et al. 2018) displaying proliferation, with functional and morphological changes noted in astrocytes and microglia (Ransohoff and Brown 2012; Pocock and Kettenmann 2007). These alterations might contribute to the behavioral outcomes associated with substance abuse (Coller and Hutchinson 2012; Miguel-Hidalgo 2009). Importantly, repeated exposure to JWH-018 during adulthood induces astrogliosis and microgliosis in specific DAergic areas (Pintori et al. 2021).

Similarly to other drugs of abuse, exposure to THC and SCRAs induces alteration in brain cytokine production, leading to either anti-inflammatory (Bhatt et al. 2021; Fields et al. 2020; Tanaka et al. 2020) or pro-inflammatory (Bayazit et al. 2017; Zamberletti et al. 2015) effects. Despite the dramatically increased use of SCRA among young adults

(Wagner et al. 2014; Miliano et al. 2018; EMCDDA 2019), their impact on brain function and behavior at adulthood represents an important unanswered health question. In addition, the absence of a reliable adolescent animal model mimicking the voluntarily daily intake of SCRA impedes advancements in the field. Therefore, in this study, we developed an animal model to investigate the reinforcing properties of JWH-018 in male adolescent mice and to evaluate the role of CB1Rs in modulating JWH-018 IVSA. Since growing investigations indicate that SCRA produces compulsive, repetitive, and impulsive behaviors (McDonald et al. 2003; Clayton et al. 2017; Mensen et al. 2019), we also investigated these behavioral outcomes in adult mice that self-administered JWH-018 during adolescence by evaluating marble burying, nestlet shredding, and wire-beam bridge tests. In parallel, potential changes in glial cells (astrocytes and microglia) and of cytokines/chemokines (e.g., IL2, IL13, RANTES) expression were investigated at adulthood after adolescent exposure to JWH-018. Lastly, since JWH-018's activity is CB1R-mediated (De Luca et al. 2015), and passive administration of JWH-018 down-regulates the expression of CB1 receptors in DAergic terminal areas of adult rats (Pintori et al. 2021), we evaluated whether JWH-018 IVSA during adolescence can induce long-term alterations in the expression of CB1Rs in brain areas involved in addiction and motivated behavior, such as the cortex and striatum.

# Materials and methods

## Animals

Adolescent CD1 male mice (Envigo, Netherlands), weighing 22–27 g, were used from postnatal day (PND) 25 to 80 for intravenous self-administration and subsequent behavioral and neurochemical studies. Mice were housed in groups of three to six per cage with standard conditions of temperature (21 ± 1 °C) and humidity (60%) under a 12-h light/dark cycle (lights on at 7.00 AM) and with ad libitum access to water and food (Mucedola, Italy) until the intravenous self-administration (IVSA) experiments. All animal care procedures and experiments were carried out in accordance with European Council directives (609/86 and 63/2010) and in compliance with the animal policies issued by the Italian Ministry of Health and the Ethical Committee for Animal Experiments (CESA, University of Cagliari). We made all efforts to minimize pain and suffering and to reduce the number of animals used, according to the 3Rs principles.

## Drugs

JWH-018, AM251, and AM630 were purchased from Tocris (Bristol, UK). Drugs were solubilized in 0.5% EtOH, 0.5%
Tween 20, and 99% saline. AM251 and AM630 (CBR1- and CBR2-antagonist/inverse agonists, respectively) were administered intraperitoneally (i.p.) 30 min prior to JWH-018 IVSA at different doses depending on the group of animals; AM251: 0.3–1.0 mg/kg (volume 10 mL/kg); AM630: 0.5 and 1.0 mg/kg (volume 10 mL/kg).

## Overall experimental design and study group

This study was designed to characterize the behavioral and neurobiological consequences of adolescence JWH-018 IVSA at adulthood (Fig. 1). First, we performed IVSA experiments in adolescent mice (PND 30–55) to assess (i) the JWH-018 dose-response curve (Experiment I); (ii) the response rates in different reinforcement IVSA schedules (FR1-FR3-PR; Experiment II); (iii) the response rates in different JWH-018 IVSA phases (Acquisition, Extinction, Reacquisition; Experiment III), and (iv) the effect of CBRs blockade on JWH-018 IVSA (Experiment IV). Afterwards, mice from Experiment II (IVSA from PND 34 to 53) were used for behavioral and neurochemical characterization at adulthood. In particular, after 3 days of recovery from surgery (PND 31–33), IVSA experiment started under different schedules of reinforcement from PND 34 to 53 for 7 days/week. At adulthood, after a drug-free washout period (~3 weeks), from PND 77 to

79 animals were randomly divided into different groups to perform behavioral tests, with a sub-group of the mice of each treatment group assigned to repetitive/compulsive-like behaviors' evaluation (marble burying and nestlet shredding tests) and another sub-group assigned to risk-taking behaviors' evaluation (wire-beam bridge). At PND 80, mice were sacrificed for subsequent neurochemical assays. In particular, a sub-group of the mice of each group were randomly assigned to immunohistochemical evaluations (GFAP and IBA-1 immunoreactivity), and another sub-group to western immunoblotting (COX-2, EAAT2, CB1 expression) and cytokines measurements. The experimental group sizes ($n \ge 5$) were chosen based on our previous experimental protocols (Pintori et al. 2021; Castelli et al. 2014) and are shown in the figure legends. Due to experimental protocol criteria (e.g., acquisition criteria during IVSA phase) and/or technical issues (e.g., catheter obstruction or damage), some animals were excluded from statistical analysis, thus reducing group sizes in few cases.

## Intravenous self-administration studies during adolescence

Detailed descriptions of surgery and IVSA methods are included in the Supplementary Information (SI).

<figure><img src="image_3.png" /><figcaption>**Fig. 1** Overall experimental design. Groups of male CD1 mice studied by different experimental procedures, during adolescence and adulthood. IVSA, intravenous self-administration; PND, postnatal day. JWH-018 IVSA: Experiment I ($n=8$ per group); Experiment II (JWH-018 $n=10$; Veh $n=15$); Experiment III ($n=7$); Experiment</figcaption></figure>

IV ($n=5$). Behavioral tests: marble burying and nestlet shredding ($n=5$ per group); wire-beam bridge ($n=5$ per group). Neurochemical assays: immunohistochemistry ($n=5$ per group); Western Blot and cytokine measurements (JWH-018 $n=5$; Veh $n=10$)
## Characterization of JWH-018 dose-response curve in the IVSA experimental paradigm (Experiment I)

The first experiment was aimed at characterizing a dose-response curve of JWH-018 (2.5–15 µg/kg/25 µl infusion) in adolescent mice. Mice IVSA experiment was carried out under Fixed Ratio (FR) 1 schedule of reinforcement (1 right lever press: 1 injection; 20-s time-out with light off, session duration 2 h), from PND 30 until PND 53 (24 sessions). During time-out (TO) period, right (active) lever presses had no programmed consequences, while left (inactive) lever presses were never associated with programmed consequences.

## Characterization of response rates in different reinforcement IVSA schedules (FR1, FR3, PR; Experiment II)

Once the dose at which adolescent mice acquired operant behavior was established (7.5 µg/kg/25 µl infusion), we used different FR protocols to evaluate the reinforcing properties of JWH-018. After a first acquisition phase under FR1 schedule of reinforcement, in which the number of lever pressing achieved 80% of stability for at least three consecutive sessions (7 sessions in total), mice underwent FR3 (3:1) for 12 sessions. The same protocol of IVSA was used for the control group, which was exposed to Vehicle solution (0.5% EtOH, 0.5% Tween 20, and 99% saline). During the last session of the JWH-018 IVSA, after at least 75% responding on the active lever in three consecutive FR3 sessions, the experiment was performed under a Progressive Ratio (PR) schedule of reinforcement in which the number of active lever presses required to obtain each subsequent injection was based on the adapted exponential sequence: 1, 2, 4, 6, 9, 12, 15... (Valentini et al. 2013). PR sessions lasted for 2 h or until mice did not complete the ratio for the delivery of at least one injection within 1 h.

## Characterization of response rates in different JWH-018 IVSA phases (Acquisition, Extinction, Reacquisition; Experiment III)

After the acquisition phase under FR1-FR3 schedules (see acquisition criteria), a different group of mice underwent extinction and reacquisition phase protocols to assess seeking behavior and reacquisition of operant behavior after the extinction phase to JWH-018. Extinction session schedule was identical to the acquisition schedule, except for the absence of any delivery of JWH-018 infusion. After 6 sessions performed in extinction phase, the protocol was switched to reacquisition phase for 7 sessions in the same condition of acquisition.

## Effect of CBRs blockade on JWH-018 IVSA (Experiment IV)

To investigate the role of CBRs on operant behavior, in two separate groups of animals subjected to the same protocol of the *Experiment II* (except for PR), we evaluated the effects of the CB1R antagonist/inverse agonist AM251 (0.3–1.0 mg/kg i.p.), and the CB2R antagonist/inverse agonist AM630 (0.5, 1.0 mg/kg i.p.) injections on IVSA behavior. AM251, AM630, or vehicle has been administered 30 min before starting one of the IVSA FR3 session that reached the established criteria of stability (see acquisition criteria); before each antagonist pretreatment, responsiveness for JWH-108 was established to the same stability criteria.

## Behavioral studies at adulthood

For the behavioral studies, after a drug-free period (~3 weeks) from the last session of IVSA, adult mice (PND 77–79) from *Experiment II* were tested in marble burying, nestlet shredding and wire-beam bridge tests to assess potential repetitive/compulsive-like and risk-taking phenotypes, respectively (Fig. 1). To minimize stress carry-over effects, mice were subjected to these behavioral tasks in the same experimental room (light intensity between 20 and 30 lx), with an inter-test interval of 24 h and performed in the following order: marble burying, nestlet shredding, and wire-beam bridge tests.

### Marble burying test

Marble burying test was performed in a transparent plastic cage (50 cm L, 30 cm W, 20 cm H) containing 5 cm of fresh hardwood chip bedding. Twenty standard glass marbles (1.5 cm in diameter, arranged in five rows of four marbles each) were placed uniformly over the surface of bedding. Mice were individually placed in the cage and their activity was recorded for 20 min. At the end of the session, animals were gently removed, and the number of marbles totally (≥ 95%) buried was counted. In order to avoid the presence of olfactory cues, bedding was replaced and marbles were cleaned between each mouse test.

### Nestlet shredding

Nestlet shredding test was performed in the same type of cage used for marble burying, but with 3 cm of fresh hardwood chip bedding containing a 5×5 cm packed cotton nestlet (Ancare Corp; Bellmore, NY) laid on the top of the bedding material. Mice were individually placed in the cage and their activity was monitored for 75 min. Then, the remaining cotton nestlet was dried overnight and the amount (i.e., percentage) of the nestlet shredded was determined by weighing the day after.
## Wire-beam bridge

This test was performed as previously described, with slight modifications (Frau et al. 2017). The apparatus consisted of 50-cm high Plexiglas platform and a 100-cm high Plexiglas wall, oppositely placed at 50 cm distance. Platforms were connected by a horizontal, flexible wire-mesh metallic grid. Mice were individually placed in the proximity of the edge (3 cm from the edge) of one platform, to make the starting position uncomfortable and promote movement. Behavioral measures, as index of behavioral disinhibition, were scored for 5 min and included the latency to access the bridge (with all 4 paws on it) and to first movement; movement duration and frequency; stretch attend postures and head dipping phenotypes.

## Immunohistochemistry

At the end of the behavioral tests (PND 80), a sub-group of the animals from the *Experiment II* were selected for immunostaining analyses, while another sub-group for cytokines measurements and western immunoblotting (see Fig. 1).

### Brain tissue preparation and GFAP and IBA-1 immunofluorescent staining

Procedures were carried out as previously described (Castelli et al. 2014; Pintori et al. 2021) (for details, see SI).

### Imaging and quantitative analysis of GFAP and IBA-1 immunofluorescent staining

An Olympus IX 61 microscope and an Olympus 12-bit cooled F View II camera (Hamburg, Germany) were used for observations and for capturing the images, respectively (For details, see SI).

## Cytokine measurements and Western immunoblotting

### Sample processing

Mice were sacrificed by cervical dislocation; striatum and cortex were quickly collected and snap frozen in liquid nitrogen and stored at –80 °C. For cytokine measurements and immunoblotting for excitatory amino acid transporter [(EAAT2) or glutamate transporter (GLT-1)] and cyclooxygenase 2 (COX-2), tissues were prepared following the

instruction of Bio-Plex Cell Lysis Kit Product Insert (for details, see SI).

## Cytokine measurements

Brain cytokine concentrations were measured using a fully quantitative ELISA-based chemiluminescent assay (BioRad 23-plex mouse kit), which simultaneously detects cytokines, chemokines, and growth factors. All samples were run in duplicate and assayed with the BioRad reagent kit and cell lysis for tissue samples, according to the manufacturer's instructions. Lyophilized cytokines standards containing cytokines: [(IL)1α, IL1β, IL2, IL3, IL4, IL5, IL6, IL9, IL10, IL12(p40), IL12(p70), IL13, IL17, interferon (IFN) γ, TNFα; chemokines: eotaxin, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein (MIP)1α, MIP1β, regulated on activation normal T cells expressed and secreted (RANTES), keratinocyte derived chemokine (KC/GRO/CXCL1), and growth factors: granulocytes macrophage colony-stimulating factor (GM-CSF) and granulocyte (G)-CSF] were reconstituted to a master standard stock (for details, see SI).

## EAAT2, COX-2, and CB1R immunoblotting

Samples (cortex and striatum) were thawed on ice and diluted to final concentration of 12 µg/µl protein.

Samples with equal amounts of protein (60 µg) mixed with Laemmli loading buffer were denatured at 70 °C for 10 min and loaded on gradient gel (4–12% NuPAGE Bis–Tris mini gels 15 well 1 mm gels, Life Technologies, CA, USA). To identify the specific bands, internal molecular weight (MW) standards (Precision Plus Protein Western C Standards, Bio-Rad, Hercules, CA, USA) were run in parallel. Then, proteins were transferred onto polyvinylidene difluoride (PVDF) membranes following the company's protocol (Amersham GE Healthcare, UK). The protein transfer was checked by the ponceau red coloring of the membrane. Membranes were blocked for 1 h at room temperature using a mixture of 20 mM Tris base, 137 mM sodium chloride, and 0.1% Tween 20 (TBS-T) containing 5% BSA or dry powder milk before incubation overnight at 4 °C with the primary antibodies. The following primary antibodies were used: mouse monoclonal anti-EAAT2 (1:500; SC-365634; Santa Cruz, Dallas, TX), mouse monoclonal anti-COX-2 (1:100; SC-376861; Santa Cruz, Dallas, Texas, USA), and mouse monoclonal anti-β-Actin (1:2000; mAbcam 8226; Abcam, Cambridge, UK). For detection of COX-2, the blot was stripped with Restore Western Blot Stripping Buffer (Thermo Scientific, Rockford, IL) and re-blotted with the anti-COX-2 overnight at 4 °C. Blots were incubated with goat horseradish peroxidase (HRP) conjugated secondary anti-mouse antibody
JWH-018 dose-response curve

a JWH-018 (µg/kg/inf)

<figure><img src="image_4.png" /></figure>

b JWH-018 intake

<figure><img src="image_5.png" /></figure>

Response rate in different reinforcement IVSA schedules (FR1, FR3, PR)

C JWH-018 IVSA (7.5 µg/kg/inf)

<figure><img src="image_6.png" /></figure>

d JWH-018 intake

<figure><img src="image_7.png" /></figure>

Response rate in different JWH-018 IVSA phases

e JWH-018 IVSA (7.5 µg/kg/inf)

<figure><img src="image_8.png" /></figure>

f JWH-018 intake

<figure><img src="image_9.png" /></figure>

Effect of CB1R blockade on JWH-018 IVSA

g CB1R blockade

<figure><img src="image_10.png" /></figure>
►Fig. 2 Characterization of JWH-018 IVSA in adolescent mice. (a) JWH-018 dose-response curve in the IVSA experimental paradigm (Experiment I). Results are expressed as mean ± SEM of the number of active (circles) and inactive (triangle) lever presses exhibited during each 2 h daily session under FR1 reinforcement schedules at different JWH-018 doses (2.5–15 µg/kg/inf). *p < 0.05, ** p < 0.01 vs inactive lever presses (two-way ANOVA; Sidak's post hoc test); N = 8 per group. (b) Daily intake during JWH-018 IVSA dose-response curve. Data are expressed as µg/kg of JWH-018 self-administered during each 2 h daily session. Each bar represents the mean ± SEM of the drug self-administered at each dose during the IVSA sessions as indicated in the panel A. *p < 0.05, **** p < 0.0001 vs all the other groups (one-way ANOVA; Sidak's post hoc test); n = 8 per group. (c, d) Response rates in different reinforcement IVSA schedules (FR1-FR3-PR; Experiment II). Results are expressed as mean ± SEM of the number of active (circles) and inactive (triangle) lever presses exhibited during each 2 h daily session under FR1, FR3, or PR reinforcement schedules during JWH-018 (7.5 µg/kg/inf) or vehicle (25 µl/inf) IVSA. *p < 0.05, ** p < 0.01, *** p < 0.001 vs inactive lever presses; +++ p < 0.001 vs FR3 session (mean of the last 3 sessions) (two-way ANOVA; Sidak's post hoc test); JWH-018: N = 10; Veh: n = 15. (e) Response rates in different JWH-018 IVSA phases (Acquisition, Extinction, Reacquisition; Experiment III). Results are expressed as mean ± SEM of the number of active (circles) and inactive (triangle) lever presses exhibited during each 2 h daily session during acquisition, extinction, and reacquisition phases of JWH-018 IVSA (7.5 µg/kg/inf). *p < 0.05, ** p < 0.01 vs inactive lever presses (two-way ANOVA; Sidak's post hoc test); n = 7 per group. (f) Effect of CB1R blockade on JWH-018 IVSA (Experiment IV). Results are expressed as mean ± SEM of the number of active (black bars) and inactive (white bars) lever presses exhibited 30 min after intraperitoneal injection of vehicle or AM251 (0.3–1.0 mg/kg). *p < 0.05 ** p < 0.01 vs Vehicle (Veh) (one-way ANOVA; Sidak's post hoc test); n = 5 per group

(1:5000; Vector, CA, USA) for 1 h at RT, and after TBS-T wash, incubated with the chemiluminescent detection solution Clarity Western ECL Substrate (Bio-Rad, Hercules, CA, USA) according to the protocol provided by the company, and visualized by ImageQuant LAS-4000 (GE Healthcare, Little Chalfont, UK). The signals of the specific bands were normalized with the densities of the corresponding band of endogenous protein β-Actin. Therefore, the normalized data were expressed as a protein/β-actin ratio. Densitometric analysis of the acquired signals was carried out, using the Image Studio Lite Software (LI-COR Biosciences (RRID:SCR_014211, Li-Cor, http://www.licor.com/bio/products/software/image_studio_lite/). With regard to CB1R immunoblotting, protein extracts were mixed with denaturing 4× Laemmli loading buffer and warmed for 30 min at 37 °C. Samples (18–24 µg per lane) were analyzed on 4–20% precast polyacrylamide gels (Bio-Rad, Hercules, California) and transferred onto PVDF membranes 0.45 µm (Merk Millipore, Billerica, MA). Membranes were blocked in a mixture of Tris-buffered saline and polysorbate 20 (20 mM Tris–HCl pH 7.6, 150 mM NaCl, 0.05% Tween 20) containing 5% of non-fat milk for 1 h at RT. The membrane was incubated at RT for 1 h using antibodies rabbit anti-CB1R (CB1,

ab23703; 1:200, Abcam, Cambridge, UK), mouse anti-alpha tubulin (used as loading control) (sc69969; 1:5000, Santa Cruz, Dallas, US). After the transfer step, the membranes were incubated for 1 h with the primary antibody anti-CB1R. After stripping with Restore Western Blot Stripping Buffer, membranes were re-blotted with a mouse monoclonal anti-alpha-tubulin antibody for normalization. Bound primary antibodies were detected with HRP-linked antibodies (1:2000, Cell Signaling Technology, Danvers, MA) and visualized by enhanced chemiluminescence detection (Clarity Western ECL Substrate, Bio-Rad, Hercules, California). The optical densities of immunoreactive bands were quantified by the Image Lab software (Bio-Rad, Hercules, California) after acquisition on ChemiDoc Touch (Bio-Rad, Hercules, California, US).

## Statistical analysis

All data are presented as mean ± SEM. Data were tested for normal distribution using Shapiro–Wilk's test. Non-parametric test (i.e., Mann–Whitney *U*-test) was chosen when data were found not to be normally distributed. For IVSA studies, the response rates exhibited during each IVSA phase (Acquisition, Extinction, Reacquisition) schedule (FR1-FR3), and JWH-018 dose tested (2.5–15 µg/kg/25 µl infusion) were analyzed separately by two-way repeated measures (RM) ANOVA with response (i.e., active or inactive lever presses), session and/or schedule (mean of the last 3 FR3 sessions, PR) as factors, followed by Sidak's multiple comparisons. For RM tests, whenever we could not assume sphericity, a Geisser-Greenhouse correction was carried out by GraphPad Prism 8 software (GraphPad Prism). Considering JWH-018 intake, the data (mean ± SEM of JWH-018 consumption at each dose during 2 h of IVSA sessions) were analyzed by RM one-way ANOVA followed by Sidak's post hoc test. The same statistical analysis was used to assess the effects of CBRs blockade on IVSA. For neurochemical assays, to assess the effect of JWH-018 IVSA on cytokine levels and on GFAP and IBA-IR, data were analyzed by using two-way ANOVA, with treatment and brain areas as factors, followed by Tukey's multiple comparison. Then, the effect of IVSA on cytokines, GFAP, and IBA-1-IR within each brain area was analyzed by Student's *t*-test. For behavioral and Western Blot experiments, the data were analyzed by using Student's *t*-test. Differences were considered significant at *p* < 0.05. Effect sizes were calculated by using Cohen's *d* or Hedges's *g* when sample sizes were equal or not equal, respectively. Post hoc tests were conducted only when a significant main effect and/or interaction were detected. All analyses were performed using the GraphPad software package (Prism, version 8; GraphPad, San Diego, California, USA).
# Results

## Adolescent IVSA studies

### Characterization of JWH-018 dose-response curve in the IVSA experimental paradigm (Experiment I)

To characterize the pattern of response of CD1 male adolescent mice (PND 30–53), we investigated the JWH-018 dose-response curve using the IVSA experimental paradigm. Based on previous studies performed in adult C57 mice (De Luca et al. 2015), we chose a range of doses of JWH-018 from 2.5 to 15 µg/kg/25 µl infusion (lever pressing, FR 1:1). Two-way ANOVA analysis (response × session) performed for the dose of 2.5, 5, 10, and 15, revealed no significant main effects or interaction. Only at the dose of 7.5 µg/kg/inf, two-way ANOVA showed a main effect of response ($F_{(1,14)}$=11.37, *p* = 0.0046). Sidak's post hoc test of the response main effect showed a significant difference between active and inactive lever presses in the 11th (*p* < 0.05, Cohen' *d* = 1.7421), 15th (*p* < 0.01, Cohen' *d* = 2.1085), 16th (*p* < 0.05, Cohen' *d* = 2.1583), and 17th sessions (*p* < 0.05, Cohen' *d* = 2.1456) (Fig. 2(a)). Consistently, RM one-way ANOVA analysis revealed a significant effect of JWH-018 dose ($F_{(1,66,11,65)}$=48.68, *p* < 0.0001). Sidak's post hoc test showed higher JWH-018 intake at the dose of 7.5 µg/kg/inf as compared to the doses of 2.5 (*p* < 0.0001, Cohen' *d* = 5.3309), 5.0 (*p* < 0.001, Cohen' *d* = 4.1178), and 15 (*p* < 0.001, Cohen' *d* = 5.0814) µg/kg/inf (Fig. 2(b)).

### Characterization of response rates in different reinforcement IVSA schedules (FR1-FR3-PR; Experiment II)

Once the dose at which adolescent mice acquired operant behavior was established (7.5 µg/kg/25 µl infusion), we used different schedules of reinforcement (Fixed and Progressive Ratio) to evaluate the reinforcing properties of JWH-018. Under FR1 schedule, two-way ANOVA analysis (response × session) revealed no significant main effects or interaction. On the contrary, under FR3 schedule, two-way ANOVA analysis showed a main effect of response ($F_{(1,18)}$=51.88, *p* < 0.0001), of session ($F_{(3,42,61,64)}$=7.02, *p* = 0.0002), and of response × session interaction ($F_{(11,198)}$=2.70, *p* = 0.0029). Sidak's post hoc test revealed significant differences between active and inactive lever presses in the 8th (*p* < 0.01, Cohen' *d* = 2.4539), 12th (*p* < 0.01, Cohen' *d* = 2.5103), 13th (*p* < 0.05, Cohen' *d* = 1.6962), 14th (*p* < 0.05, Cohen' *d* = 1.7843), 15th (*p* < 0.05, Cohen' *d* = 1.8585), 16th (*p* < 0.001, Cohen' *d* = 2.7341) 17th (*p* < 0.05, Cohen' *d* = 1.5941), and 19th

(*p* < 0.001, Cohen' *d* = 2.5379) sessions (Fig. 2(c)). Considering differences between FR3 and PR schedule, two-way ANOVA analysis showed a main effect of response ($F_{(1,18)}$=20.45, *p* = 0.0003), of schedule ($F_{(1,18)}$=15.43, *p* = 0.0010), and of response × schedule interaction ($F_{(1,18)}$=5.23, *p* = 0.034). Sidak's post hoc test revealed a significant increase of active but not inactive lever presses during PR session as compared to FR3 session (*p* < 0.001, Cohen' *d* = 1.2647). Consistently, a control group of mice failed to acquire Vehicle IVSA both under FR1 and FR3 schedule, confirming that the operant behavior was specifically directed at obtaining JWH-018 (Fig. 2(d)).

### Characterization of response rates in different JWH-018 IVSA phases (Acquisition, Extinction, Reacquisition; Experiment III)

To further assess the abuse potential of JWH-018, we evaluated seeking behaviors for JWH-018 through the extinction phase and the following reacquisition of operant behavior. Under FR1 schedule, two-way ANOVA analysis (response × session) revealed no significant main effects or interaction. On the contrary, under FR3 schedule, two-way ANOVA analysis showed a main effect of response ($F_{(1,12)}$=15.84, *p* = 0.0018), of session ($F_{(2,83,34,02)}$=9.19, *p* = 0.0002), and of response × session interaction ($F_{(5,60)}$=5.18, *p* = 0.0005). Sidak's post hoc test revealed significant differences between active and inactive lever presses in the 7th (*p* < 0.05, Cohen' *d* = 2.0024), 9th (*p* < 0.05, Cohen' *d* = 1.989), 10th (*p* < 0.05, Cohen' *d* = 1.9389), 11th (*p* < 0.05, Cohen' *d* = 1.9257), and 12th (*p* < 0.05, Cohen' *d* = 1.995) sessions. Again, no difference in lever responding were observed during extinction phase, while two-way ANOVA analysis during reacquisition showed a main effect of response ($F_{(1,12)}$=27.57, *p* = 0.0002) and of response × session interaction ($F_{(6,72)}$=2.83, *p* = 0.016). Sidak's post hoc test revealed significant differences between active and inactive lever presses in the 19th (*p* < 0.05, Cohen' *d* = 2.0057), 23th (*p* < 0.05, Cohen' *d* = 2.4367), 24th (*p* < 0.01, Cohen' *d* = 2.7885), and 25th (*p* < 0.01, Cohen' *d* = 2.8090) sessions (Fig. 2(e)).

### Effect of CBRs blockade on JWH-018 IVSA (Experiment IV)

To investigate the involvement of CB1R on operant behavior, we studied the effect of the administration of the selective antagonist/inverse agonist AM251 (0.3–1.0 mg/kg i.p.; 30 min before the IVSA FR3 session) on JWH-018 (7.5 µg/kg/25 µl infusion) IVSA behavior. RM one-way ANOVA analysis revealed a significant effect of AM251 dose ($F_{(1,23,4,92)}$=12.54, *p* = 0.0015). Sidak's post hoc test showed a significant decrease of active lever presses at the dose of 0.7 (*p* < 0.05, Cohen' *d* = 2.4027) and 1.0 (*p* < 0.01,
Cohen' *d*=4.3616) mg/kg of AM251 as compared to vehicle (Fig. 2(f)). On the other hand, data showed that the administration of the CB2R antagonist/inverse agonist AM630 (0.5 and 1.0 mg/kg i.p.) did not affect IVSA operant behavior (Supplementary Fig. 1S).

## Behavioral studies at adulthood

### Marble burying and nestlet shredding test

The marble burying test showed that adolescent exposure to JWH-018 increased the number of completely covered marbles compared to vehicle group ($t_{(8)}$=2.51; *p*=0.036; +33%, Cohen' *d*=1.5874; Fig. 3(a)). Consistently, nestlet shredding test showed that adolescent exposure to JWH-018 increases nestlet shredding compared to their vehicle counterparts ($t_{(8)}$=2.97; *p*=0.018; +140%, Cohen' *d*=1.8767; Fig. 3(b)). These data suggest that JWH-018 self-administration during adolescence exerted permanent, long-lasting repetitive/ compulsive-like behavioral effects at adulthood.

### Wire-beam bridge

In contrast with marble burying and nestlet shredding data, repeated exposure to JWH-018 during adolescence failed to modify a number of risk-taking behaviors in the wire-beam bridge task assessed at adulthood. Indeed, adult JWH-018 mice and their vehicle counterparts exhibited similar risk-assessment phenotypes when positioned on an unstable suspended bridge. Accordingly, analyses showed no significant differences in the latency to cross the bridge as well as to the first movement, duration, and number of movements, number of stretch-attend posture episodes, duration, and number of head dipping (Fig. 3(c)-(i)).

## Immunohistochemistry and neurochemical studies

### Adolescent JWH-018 IVSA results in long-term changes of IBA-1 and GFAP immunoreactivity in specific brain areas

To determine whether adolescent exposure to JWH-018 was able to induce enduring changes in glial cells (astrocytes and microglia), we measured the levels of specific markers of neuroinflammation (IBA-1 and GFAP) in prefrontal cortex (PFC), NAc (shell and core), and caudate-putamen (CPu) of adult mice that underwent IVSA during adolescence. Two-way ANOVA of IBA-1 showed a main effect of treatment ($F_{(1,24)}$=16,70, *p*=0.0004), brain area ($F_{(3,24)}$=8,176, *p*=0.0006), but not brain area × treatment interaction. To evaluate the effect of adolescent JWH-018 IVSA on IBA-1 in each brain area, data were also analyzed separately. Student's *t*-test showed increased expression of IBA-1, a marker of activated microglia within the NAc core and shell ($t_{(6)}$=2.47;

*p*=0.0482, Cohen' *d*=1.7451; +9%; $t_{(6)}$=3.02; *p*=0.0235, Cohen' *d*=2.0545; +11% respectively) and CPu ($t_{(6)}$=3.58; *p*=0.0116, Cohen' *d*=1.1586; +15%) of mice subjected to adolescent JWH-018 IVSA with respect to control (Veh); no significant differences in IBA-1 were observed in the PFC (Fig. 4(a)). Moreover, as shown in Fig. 4(c), IBA1 staining revealed that most of microglial cells displayed a rounded ameboid-like aspect, characteristic of activated microglia, while resting microglia in the NAc of control mice (Veh) showed a ramified appearance. Considering GFAP expression, two-way ANOVA showed a main effect of brain area ($F_{(3,25)}$=38,76, *p*<0.0001), treatment ($F_{(1,25)}$=12,68, *p*=0.0015), but not brain area × treatment interaction. However, analyzing each brain region separately, Student's *t*-tests detected a significant decrease of GFAP levels in the CPu of JWH-018 mice compared to Veh group ($t_{(6)}$=2.92; *p*=0.0268, Cohen' *d*=2.066; -29%); a downward trend, but non-significant, of GFAP expression was also observed in all the other analyzed brain areas in JWH-018 mice indicating possible astrocytopathy (Fig. 4(b)). Taken together, our data revealed an association between adolescent IVSA of JWH-018 and long-term microglia activation as well as potential effects on astrocyte density.

### Adolescent JWH-018 IVSA results in altered cytokine expression in the brain of adult mice

We investigated the long-term effects of JWH-018 IVSA during adolescence on the concentration of cytokines/chemokines in the brains of adult mice using a fully quantitative ELISA-based chemiluminescent assay. Two-way ANOVA (treatment × brain area) for the chemoattractant protein MPC1 showed significant main effect of treatment ($F_{(1,19)}$=8,878, *p*=0.0077), of brain area ($F_{(1,19)}$=7,813, *p*=0.0115), and of treatment × brain area interaction ($F_{(1,19)}$=5366, *p*=0.0319). Tukey's post hoc revealed a significant increase of MCP1 (*p*<0.01; +80%, Hedges' *g*=1.7416) in striatum of JWH-018 group compared to the control group (Veh). Moreover, the increase of this chemoattractant protein was significantly higher (*p*<0.05, Cohen' *d*=1.5415; +75%) in the striatum than in the cortex of JWH-018 IVSA mice (Fig. 5). On the contrary, two-way ANOVA for IL2, IL13, and RANTES showed a significant main effect of brain area [IL2 ($F_{(1,14)}$=7109, *p*=0.0184; IL13 ($F_{(1,17)}$=19,712, *p*=0.00035); RANTES ($F_{(1,21)}$=38,764, *P*=0.000004)], but no effect of treatment nor treatment × brain area interaction for any cytokine analyzed. Subsequently, data were analyzed separately using a Student's *t*-test. As shown in Fig. 6(a)-(c)), adolescent JWH-018 IVSA induced a significant decrease in the cortex of IL2 ($t_{(8)}$=3.99; *p*=0.004, Hedges' *g*=2.5721; -20%) and IL13 ($t_{(9)}$=3.44; *p*=0.007, Hedges' *g*=2.0856; -16%)
## Behavioral tests

a **marble burying**

<figure><img src="image_11.png" /></figure>

b **nestlet shredding**

<figure><img src="image_12.png" /></figure>

### wire-beam bridge

c

<figure><img src="image_13.png" /></figure>

d

<figure><img src="image_14.png" /></figure>

e

<figure><img src="image_15.png" /></figure>

f

<figure><img src="image_16.png" /></figure>

g

<figure><img src="image_17.png" /></figure>

h

<figure><img src="image_18.png" /></figure>

i

<figure><img src="image_19.png" /></figure>

**Fig. 3** Long-term behavioral effects of JWH-018 IVSA in marble burying (MB) (a), nestlet shredding (b), and wire-beam bridge (c–i) tests. Results are expressed as mean ± SEM (a) of the number of marbles buried in the MB test, (b) of the percentage of nestlets shredded in the nestlet shredding test, (c, d) of the latency (sec) to cross the

bridge and to first movement, (e, f) of the movement duration (sec) and bouts, (g, h) of the number of stretch attend postures (SAP) and head dipping bouts, and (i) of the head dipping duration (sec) in the wire-beam bridge test. \* *p* < 0.05 vs. vehicle-treated mice; (unpaired Student's *t*-test); *n* = 5 per group

levels, while RANTES level was significantly increased (*t*_{(10)} = 2.50; *p* = 0.031, Hedges' *g* = 1.4680; +15%). Moreover, in the cortex, we observed an upward trend of IL1α, IL3, IL-4, IL5, IL17α, KC, and MCP-1 levels, a downward trend of IL2 levels, with no variation of IL1β, IL6, IL9, IL10, IL12 (p40), IL12 (p70), IFNγ, and Eotaxin expression, and undetectable TNFα and G-CSF at 300 µg

proteins/well (see Table 1 for details). In the striatum, we observed a downward trend of IL2, IL3, IL13, IL17α, MIP1α, and MIP1β expression, no variation in IL1α, IL1β, IL4, IL5, IL6, IL9, IL10, IL12 (p40), IL12 (p70), KC, RANTES, and G-CSF, and undetectable TNFα and GM-CSF at the same concentration reported above (see Table 1 for details).

<figure><img src="image_20.png" /></figure>
**Fig. 4** Long-term effects of JWH-018 IVSA on IBA-1 and GFAP immunoreactivity in specific brain areas. Adolescent JWH-108 IVSA at adulthood: (a) increased the number of IBA-1 positive cells in the dorsal CPu and in the NAc core and shell; \*p<0.05 compared to Vehicle (Veh) group (unpaired Student's t-test); *n*=4 per group, and (b) decreased GFAP immunoreactivity in the CPu, with a downward trend observed in the other brain areas; JWH-018: *n*=4 per group; Veh: *n*=5 (PFC, NAc core), *n*=4 (CPu, NAc shell). Values represent mean±SEM of number of IBA-1 positive cells/mm² or percentage of GFAP-IR density; \*p<0.05 compared to Vehicle (Veh) group (unpaired Student's t-test). (c) Representative images (20×magnification) of IBA-1 and GFAP immunostaining in the CPu of adult mice that underwent JWH-018 or Veh IVSA during adolescence. Note the resting microglia (arrows, resting state in the upper left panel) and the amoeboid microglia (arrowhead, activated state in the lower left panel). Inset: higher magnification (40×) of the boxed areas

<figure><img src="image_21.png" /></figure>
<figure><img src="image_22.png" /><figcaption>**Fig. 5** Levels of chemoattractant protein MPC1 in the cortex and striatum of adult mice after adolescent exposure to JWH-018. Adolescent JWH-108 IVSA significantly increased the levels of MPC1 in the dorsal striatum at adulthood. The increase of MPC1 is higher in the striatum than in the cortex of JWH-018 mice. Data are expressed as mean±SEM of MPC1 levels, expressed as pg/ml. \*\*p < 0.01 compared to Veh group; \#p < 0.01 compared to striatum of JWH-018 group (two-way ANOVA; Tukey's post hoc test); JWH-018: n=5; Veh: n=7</figcaption></figure>

## Effect of adolescent JWH-018 IVSA on COX-2, EEAT2, and CB1Rs in specific brain areas of adult mice

Microglia activation and altered function of astrocytes are often associated with markers of inflammation such as Cox-2 (Crews et al. 2011; Cutando et al. 2013; Zamberletti et al. 2015) and modified expression of the astrocyte glutamate transporter, EEAT2 (Kim et al. 2018; Wu et al.

2008). Therefore, we investigated the expression of Cox-2 and EEAT2 in cortex and striatum of adult mice that underwent to JWH-018 IVSA during adolescence. As shown in Fig. 7(a) and (b), no significant differences in EEAT2 and Cox-2 levels between groups were observed in either the cortex or striatum. Moreover, considering the crucial role of CB1Rs in brain areas involved in addiction and motivated behaviors (López-Gallardo et al. 2012; Parsons and Hurd 2015; Zamberletti et al. 2015) and that IVSA of JWH-018 in adolescent mice is mediated by the activation of CB1Rs (Fig. 1(f)), we examined whether changes in CB1Rs expression were present in the adult cortex and striatum following adolescent JWH-018 IVSA. As shown in Fig. 7(c), no significant differences were observed in the cortex and striatum, although there is an upward trend of CB1R levels in the striatum of JWH-018 mice.

## Discussion

A major aim of the present study was to develop and characterize an animal model suitable for investigating the reinforcing properties of SCRs during adolescence as well as their behavioral and neurochemical long-term consequences at adulthood. Overall, the present study demonstrates, for the first time, that adolescent voluntary consumption of the prototypical SCRA JWH-018 alters repetitive/compulsive-like behavior, remodels glial cells, and affects cytokine expression in the brains of adult male mice.

The first key finding revealed by our investigation is that adolescent male mice (i) acquired operant behavior

<figure><img src="image_23.png" /><figcaption>**Fig. 6** Multiplex analysis of cytokines in the cortex of adult mice after adolescent exposure to JWH-018. Lower levels of (a) IL2, (b) IL13, and (c) higher levels of RANTES were detected in the cortex of adult mice following adolescent IVSA of JWH-018. Data are</figcaption></figure>

expressed as mean±SEM for each cytokine, expressed as pg/ml. \*p < 0.05 and \*\*p < 0.01 compared to Veh group (unpaired Student's t-test); JWH-018: N=4 (IL2), N=5 (IL13, RANTES); Veh: n=6 (IL2, IL13), n=7 (RANTES)

<figure><img src="image_24.png" /></figure>
<table><caption>**Table 1** Cytokine, chemokine, and colony-stimulating factor concentrations in the cortex and striatum of adult mice after adolescent JWH-018 or Vehicle IVSA. Data, expressed as a pg/ml, are mean ± SEM calculated from two independent experiments performed in duplicate. ND, not detectable: cytokines, chemokines, or colony-stimulating factors under the limit of detection. *p* < 0.05 and **p* < 0.01 compared to Veh group (unpaired Student's t-test). For MCP-1 (two-way ANOVA; Tukey's post hoc test). *p* < 0.01 compared to Veh group; #p < 0.05 compared to striatum; n = 5–6 per group</caption><thead><tr><th rowspan="2"></th><th colspan="3">Cortex</th><th colspan="3">Striatum</th></tr><tr><th>Veh</th><th>JWH-018</th><th>% change</th><th>Veh</th><th>JWH-018</th><th>% change</th></tr></thead><tbody><tr><td><strong>Cytokine</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>IL1α</td><td>1.22±0.06</td><td>1.36±0.13</td><td>+11</td><td>2.23±0.29</td><td>2.24±0.43</td><td>-</td></tr><tr><td>IL1β</td><td>10.97±0.60</td><td>10.94±1.07</td><td>-</td><td>14.38±0.80</td><td>13.99±2.95</td><td>-</td></tr><tr><td>IL2</td><td><strong>8.39±0.33</strong></td><td><strong>6.72±0.11</strong></td><td><strong>-20**</strong></td><td>17.02±3.14</td><td>11.81±4.86</td><td>-31</td></tr><tr><td>IL3</td><td>5.39±0.37</td><td>6.22±0.67</td><td>+15</td><td>15.21±0.38</td><td>12.87±1.94</td><td>-16</td></tr><tr><td>IL4</td><td>4.00±0.27</td><td>4.67±0.46</td><td>+16</td><td>9.35±0.75</td><td>8.36±1.46</td><td>-</td></tr><tr><td>IL5</td><td>1.51±0.10</td><td>1.73±0.17</td><td>+14</td><td>3.61±0.23</td><td>3.66±0.58</td><td>-</td></tr><tr><td>IL6</td><td>2.55±0.11</td><td>2.62±0.10</td><td>-</td><td>5.26±0.37</td><td>4.98±0.74</td><td>-</td></tr><tr><td>IL9</td><td>20.53±0.47</td><td>19.53±0.74</td><td>-</td><td>30.78±1.59</td><td>29.46±3.93</td><td>-</td></tr><tr><td>IL10</td><td>11.06±0.48</td><td>11.73±0.71</td><td>-</td><td>17.67±1.49</td><td>16.85±3.03</td><td>-</td></tr><tr><td>IL12(p40)</td><td>38.67±1.83</td><td>37.79±1.16</td><td>-</td><td>43.17±2.37</td><td>41.19±2.59</td><td>-</td></tr><tr><td>IL12(p70)</td><td>73.08±5.60</td><td>85.63±5.14</td><td>+17</td><td>163.70±3.90</td><td>176.00±18.05</td><td>-</td></tr><tr><td>IL13</td><td><strong>54.71±1.31</strong></td><td><strong>46.13±2.24</strong></td><td><strong>-16**</strong></td><td>83.05±3.99</td><td>69.11±11.16</td><td>-17</td></tr><tr><td>IL17</td><td>27.48±1.86</td><td>30.33±2.43</td><td>+10</td><td>56.63±1.06</td><td>46.97±7.15</td><td>-17</td></tr><tr><td>IFNγ</td><td>26.29±0.46</td><td>25.46±0.99</td><td>-</td><td>42.39±2.37</td><td>37.61±6.04</td><td>-12</td></tr><tr><td>TNFα</td><td>ND</td><td>ND</td><td>-</td><td>ND</td><td>ND</td><td>-</td></tr><tr><td><strong>Chemokine</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Eotaxin</td><td>31.94±1.20</td><td>31.31±2.10</td><td>-</td><td>70.52±3.79</td><td>54.42±7.70</td><td>-23</td></tr><tr><td>KC</td><td>20.18±1.12</td><td>22.67±2.21</td><td>+12</td><td>34.79±2.15</td><td>32.47±5.08</td><td>-</td></tr><tr><td>MCP1</td><td>19.46±1.32</td><td>21.55±2.87</td><td>+11</td><td><strong>20.97±2.01</strong></td><td><strong>37.73±5.97</strong></td><td><strong>+80**#</strong></td></tr><tr><td>MP1α</td><td>4.85±0.70</td><td>4.53±0.26</td><td>-</td><td>6.24±0.89</td><td>5.19±0.70</td><td>-17</td></tr><tr><td>MP1β</td><td>18.99±0.62</td><td>20.53±0.79</td><td>-</td><td>26.91±0.58</td><td>23.82±2.78</td><td>-12</td></tr><tr><td>RANTES</td><td><strong>13.21±0.27</strong></td><td><strong>15.12±0.84</strong></td><td><strong>+15*</strong></td><td>32.94±3.02</td><td>32.56±5.45</td><td>-</td></tr><tr><td><strong>Colony-stimulating factor</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>GM-CSF</td><td>5.46±0.40</td><td>5.89±0.67</td><td>-</td><td>ND</td><td>ND</td><td>-</td></tr><tr><td>G-CSF</td><td>ND</td><td>ND</td><td>-</td><td>7.16±0.45</td><td>7.10±0.51</td><td>-</td></tr></tbody></table>

Numbers in bold indicate significant difference between the two groups

(lever pressing) for JWH-018 with an inverted U-shaped dose-response curve; (ii) that this behavior was specifically directed at obtaining JWH-018 since it increased under a Progressive Ratio schedule of reinforcement, and was absent in vehicle mice; (iii) that JWH-018 IVSA was reduced by pretreatment of the CB1-antagonist/inverse agonist AM251. Specifically, results showed that CD1 adolescent mice acquired JWH-018 IVSA at the dose of 7.5 µg/kg/inf (Fixed Ratio 1–3), displaying higher sensitivity to this agent compared to that shown by C57BL/6 (C57) adult mice (De Luca et al. 2015), thereby confirming the reinforcing effects of SCRAs identified in Spice/K2 products (De Luca et al. 2016; Musa et al. 2020). Of note is that we established a self-administration protocol for JWH-018 using a less sensitive strain of mice, which implies greater reinforcing properties of this particular SCRA with respect to those of previous generations (Martellotta et al. 1998; Navarro et al. 2001), and with respect to THC (Tanda and Goldberg 2003; Justinova et al. 2005). We observed that as the FR for JWH-018 was increased, the difference between active and inactive lever presses became significant and that this

behavior was absent in the vehicle group. Importantly, the operant behavior was specifically directed at obtaining JWH-018, since it dramatically increased under the PR schedule of reinforcement. In contrast with what we observed with increasing doses of JWH-018 under FR1, the dose of 7.5 µg/kg/inf under a varying schedule of responding (from FR1 to FR3) hampered, unexpectedly, the acquisition process. A possible explanation is that JWH-018 intake under FR1 facilitates the acquisition process. In fact, previous studies on SCRA reported that an acute administration of WIN 55, 212–2 performed 24 h before the first session, acted as promoting factor for a faster SA acquisition of the same drug (Mendizabal et al. 2006). JWH-018 IVSA was reduced by the CB1R antagonist/inverse agonist AM251, but not by the CB2R antagonist/inverse agonist AM630. Moreover, in our experimental conditions, JWH-018 mice were not able to extinguish the operant behavior most likely due to spontaneous withdrawal signs (see Pintori et al. (2021) for description) that may drive to repetitive/persistent drug-seeking behavior and compulsive searching for the SCRA, as previously described by our group (De Luca et al. 2015).
<figure><img src="image_25.png" /><figcaption>**Fig. 7** EAAT2, COX-2, and CB1R expression in the cortex and striatum of adult mice. The protein levels of (a) EAAT2, (b) COX-2, and (c) CB1R were quantified and normalized to loading control beta-actin for COX-2, EEAT2, and alpha-tubulin for CB1R, respectively, in cortex and striatum samples from adult mice after adolescent IVSA of JWH-018 or Veh (d) representative illustration of Western blotting analysis. Values represent mean ± SEM of EAAT2, COX-2, and</figcaption></figure>

CB1R levels expressed as percentage of Veh, normalized to β-Actin and α-tubulin levels for EAAT2, COX-2, and CB1R, respectively (unpaired Student's t-test); EEAT2, JWH-018: *n*=5 (cortex, CPu); Veh: *n*=8 (cortex), *n*=7 (CPu); COX-2, JWH-018: *n*=5 (cortex, CPu); Veh: *n*=8 (cortex), *n*=7 (CPu); CB1R, JWH-018: *n*=5 (cortex, CPu); Veh: *n*=6 (cortex, CPu)

The resistance to extinction of instrumental responding after acquisition of JWH-018 IVSA (at least up to 6 consecutive sessions) could be related to the acquisition of a habit modality, consistent with a role of cannabinoids in habit learning formation (Hilário et al. 2007; Goodman and Packard 2015).

Moreover, in the present study, we reported that adolescent exposure to JWH-018 by IVSA induces repetitive/compulsive-like behaviors at adulthood, as revealed by the increase of repetitive/compulsive-like phenotypes both in the nestlet shredding and marble burying tests. Consistent with the present observations, adolescent mice treated with the SCRA 5F-MDMB-PICA for 14 consecutive days displayed repetitive/compulsive-like states at adulthood, as indexed by heightened perseverative responses in the marble burying test (Musa et al. 2020). Accordingly, Murphy et al. (2017) demonstrated that chronic administration of THC during adolescence increased nestlet shredding during adulthood;

however, adolescence animals showed a trend to statistical significance in burying marbles only immediately after THC treatment. This discrepancy could be due to the different test lengths (i.e., longer observation time in our study), and to the higher potency of JWH-018 compared to THC. It is noteworthy that marble-burying test is also often employed to assess anxiety-like behavior, as marble-burying behavior by rodents may respond to compounds with anxiolytic activity (de Brouwer et al. 2019; Thomas et al. 2009). Although in this study we did not evaluate the predictive validity of the model by testing anti-compulsive and/or anxiolytic drugs, our previous investigations (Pintori et al. 2021) and the phenotypes observed in the nestlet shredding test indicate that the heightened marble burying activity of JWH-018-treated mice likely reflects repetitive/compulsive-like rather than anxiety-like states. Previous studies have reported that chronic use of Cannabis is associated with increased
risk-taking as well as impulsive behavior and poor inhibi-
tory control (Lane et al. 2005; Wrege et al. 2014), both in
adolescent and young adult individuals (Claus et al. 2018;
O'Donnell et al. 2021). To evaluate the risk propensity of
JWH-018 exposed mice, we tested them on the wire-beam
bridge, a reliable test able to assess risk-taking behavior in
both rats and mice, and particularly susceptible to pharma-
cological manipulations of the dopamine (Bortolato et al.
2009; Frau et al. 2017; Frau et al. 2019; Festucci et al. 2021)
and cannabinoid systems (Frau et al. 2019). However, using
this test, we found that the adolescent exposure to JWH-
018 did not elicit significant engagement in risky behav-
iors at adulthood. Although risk-taking propensity (i.e., an
increase in substance use and risky sexual behaviors) has
been observed in human adolescents exposed to SCRAs
(Clayton et al. 2017), other clinical studies have shown that
adolescent Cannabis users can recover cognitive deficits by
reducing Cannabis use after 2 years from the beginning of
the experiment (Becker et al. 2018). Therefore, while we
used only one test to assess risk propensity, our findings
suggest that risky behaviors may not be a persistent neurobe-
havioral outcome of the adolescent exposure to JWH-018.

A critical finding of our study was that adolescent volun-
tary consumption of JWH-018 alters microglia, astrocytes,
and cytokine/chemokine expression in the brain of adult
mice. As reported in the introduction, although growing
evidence strongly supports a role for inflammatory changes
in the pathophysiology of drug addiction disorders, the exact
involvement of different pro-inflammatory or anti-inflamma-
tory cytokine/chemokine produced either by microglia or
astrocytes is unclear. Based on this knowledge, we decided
to use a new tool such as the multiplex assay that maximizes
cytokine/chemokine simultaneous detection in a single
sample. Specifically, we demonstrated that JWH-018 IVSA
induces at adulthood (i) an increased number of IBA1 posi-
tive cells and decreased GFAP expression in specific brain
regions, (ii) increased levels of the chemoattractant protein
MPC1 in the striatum, RANTES in cortex, and a decrease
of IL2 and IL13 in cortex. In agreement with our data, Pin-
tori et al. (2021) demonstrated that important features of
the sequelae of JWH-018 exposure at adulthood are both
astrogliosis and microgliosis. Despite the consistency of
data showing a close correlation between neuroinflamma-
tion (i.e., gliosis, microglia activation) and drug addiction
(Kim et al. 2018; Lacagnina et al. 2017; Pekny et al. 2016),
the long-term effects of SCRA IVSA on glia have not been
reported so far. Only two studies have shown that SCRAs
induce apoptosis in forebrain neuronal cultures (Tomiyama
and Funada 2014) and increase number of neural cells with
distorted and pyknotic nuclei in the NAc and hippocampus,
suggesting neurotoxic effects (Cha et al. 2015). Here, we
demonstrated for the first time that JWH-018 IVSA during
adolescence increased IBA-1 positive cells in the NAc shell

and core and in the CPu, together with a decrease of GFAP
levels in the CPu at adulthood. Images of IBA-1 staining
revealed that cells show an ameboid-like appearance, indica-
tive of an activated state of microglia. Conversely, in adult
control mice microglia displayed small soma and ramifica-
tions with non-overlapping processes, phenotypes typical
of “resting” or “surveillant” microglia (Kim et al. 2018).
Accordingly, recent studies reported that in female rats,
passive administration of THC during adolescence exerts
at adulthood a persistent neuroinflammatory profile in the
PFC associated with cognitive impairment and depressive-
like behaviors (Zamberletti et al. 2015; Gabaglio et al.
2021); Lopez-Rodriguez et al. (2014) reported an increase
of reactive microglial cells in the hippocampus of males,
whereas an opposite trend was found in females following
THC treatment. In addition, preclinical studies confirm that
methamphetamine increases GFAP levels in PFC and CPu
(Castelli et al. 2014) along with increased striatal mRNA
expression levels of IL6 family pro-inflammatory cytokines
(Robson et al. 2013). Taken together, our data confirm the
association between adolescent cannabinoid exposure and
altered levels of microglia cells in adult brains. The dis-
crepancies observed among the studies could depend on the
type of cannabinoids administered (natural or SCRA), the
type of administration (passive or active exposure), sex of
the animals, brain areas examined, and the methodologies
used to investigate the number of IBA-1 positive cells (west-
ern or immunohistochemical assay). Interestingly, immune
response dysfunctions and microglia dysregulation have
been related to many psychiatric disorders including obses-
sive-compulsive spectrum disorders (Rocha et al. 2008;
Kronfol and Remick 2000; Crews et al. 2011). Consistent
with this idea, our study showed both an increase in repeti-
tive/compulsive behaviors and an increase in IBA-1 levels
in CPu, which is included in “OCD brain circuits” (Greer
and Capecchi 2002).

Alterations in the endocannabinoid system due to adoles-
cent THC exposure could lead to modifications in immune
responses, such as cytokine expression (Bisogno and Di
Marzo 2010; Stella 2010). In the present study, we detected
all the cytokines/chemokines that we analyzed except for
TNFα, GM-CSF (striatum), and G-CSF (cortex). However,
we did not find any variations in IL1β, IFNγ, and IL10
between JWH-018 IVSA and vehicle mice. In contrast, an
increase in TNFα and a decrease of IL10 in the hippocampus
were observed by Zamberletti et al. (2016) in adult male
and female rats treated with THC during adolescence, with
the similar effects reported in the PFC of female, but not
male, rats (Zamberletti et al. 2015; 2016). In the cortex of
adult mice exposed to JWH-018 as adolescents, we found an
increasing trend in IL4 levels and an increase in RANTES,
a chemotactic cytokine that directs leukocytes to sites of
inflammation and infection, along with a decrease in IL2
and IL13 expression compared to vehicle mice. Accordingly, studies performed in Cannabis and 3,4-methylenedioxy-methamphetamine (MDMA) human users showed decreased IL2 expression in blood samples (Pacifici et al. 2007). The same group showed that long-term exposure to Cannabis decreased IL2 levels, which in turn was associated with a decrease of an inflammatory response (Pacifici et al. 2002, 2003). We also observed increased MCP1 levels in the striatum of JWH-018 mice, in line with studies reporting that other drugs of abuse, such as ethanol, increased MCP1 (Zou and Crews, 2010; Crews et al. 2011). Taken together, data suggest that JWH-018 IVSA during adolescence could lead to an altered immunological response that persists into adulthood. Indeed, Kevin et al. (2017) reported no detection in plasma of GM-CSF and TFNα in adult rats after adolescent treatment with the SCRA AB-PINACA and AB-FUBINACA. However, contrary to our results, they found decreased IL1α and IL12 after AB-FUBINACA but not AB-PINACA.

Our study showed a decrease of GFAP expression in the CPu and a downward trend also in the NAc shell and core, providing direct evidence that adolescent JWH-018 IVSA may result in a reduction of GFAP that persisted later in life. The JWH-018-induced decrease of GFAP expression is likely brain region-specific, since no alterations were detected in the PFC of JWH-018 compared to vehicle mice. Accordingly, it has been reported that THC inhibits astroglia growth in vitro (Tahir et al. 1992) and affects their development in vivo (Suárez et al. 2000). However, following adolescent treatment with THC, conflicting results have been reported regarding the levels of GFAP, with studies showing no changes, increased or decreased levels (Lopez-Rodriguez et al. 2014; Zamberletti et al. 2016). Of note, responsiveness of astrocytes to insults (e.g., injuries, inflammation, neuropsychiatric disease, drugs of abuse) ranges from astrocytopathy to astrogliosis and is characterized by several phenotypes including increased or decreased levels of GFAP and morphological features (i.e., hypertrophy/atrophy) (Kim et al. 2018). Consistently, GFAP expression and the number of astrocytes were reduced in the prelimbic cortex of ethanol-preferring rats (Miguel-Hidalgo 2005) as well as following prolonged exposure to alcohol (Franke 1995; Rintala et al. 2001).

As altered function of astrocytes and/or activated microglia in the CNS are often associated not only with modified levels of cytokines/chemokines but also with changes in the levels of iNOS and COX-2 (Crews et al. 2011; Cutando et al. 2013; Zamberletti et al. 2015) and/or decreased levels of GFAP, Aquaporin 4 and EAAT2 (Pekny et al. 2016), we measured the expression of EAAT2, an astrocyte transporter that removes synaptic glutamate in physiological conditions, in the striatum and the cortex. Down-regulation or up-regulation of EAAT2 has been reported after heroin, nicotine, cocaine, and alcohol exposure (Rao et al. 2015;

Smith et al. 2015; Linker et al. 2018; Namba et al. 2020). We observed no difference in EAAT2 expression after adolescent exposure to JWH-018 in line with Higuera-Matas et al. (2012) showing no difference in cDNA EAAT2 levels in the hippocampus of adult rats treated during adolescence with the SCRA CP55,940. We also analyzed the expression of COX-2, the inducible isoform of COX, involved in inflammatory processes and prostaglandin production (Fishbein-Kaminietsky et al. 2014). Adolescent treatment with THC increased COX-2 levels in the PFC of male and female adult rats, but not in the hippocampus of male rats (Zamberletti et al. 2015; 2016). However, we found no difference in COX-2 expression in both cortex and striatum of adult mice following JWH-018 IVSA during adolescence. Despite the small size of our experimental groups, our neurochemical results might be representative of population investigated as also pointed out by the effect size for these results found to exceed Cohen's or Hedge's convention for a large effect ($d=0.80$). Thus, the present results show not only statistical but also practical significance and application.

Finally, we evaluated the expression of CB1R in specific brain areas involved in addiction and motivated behavior (Parsons and Hurd 2015). We found no changes in the CB1Rs expression in the adult cortex or striatum of mice exposed to JWH-018 during adolescence. Different studies have reported that THC administration induced no change (Ellgren et al. 2007) or a permanent down-regulation of CB1R binding density within the amygdala and hippocampus of male (Rubino et al. 2008) and the PFC of female rats (Gabaglio et al. 2021). In addition, López-Gallardo et al. (2012) reported that chronic treatment with the SCRA CP55,940 during adolescence decreased CB1Rs expression in the hippocampus of adult male rats. However, in agreement with our data, chronic THC treatment during adolescence produced no difference in CB1R expression in the PFC of female rats (Zamberletti et al. 2015). Overall, the differences reported by studies investigating CB1R expression and function following cannabinoid administration could be ascribed to the different protocols and methods used.

These intriguing findings warrant further investigations to overcome sex differences in the recurrent use of JWH-018. Nevertheless, our model represents a useful tool to characterize the brain pathways involved in pharmacological and toxicological sequelae of SCRAs use that is a public health concern.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00213-022-06191-9.

**Acknowledgements** The authors gratefully thank Prof. Alexia Pollack for her suggestions and help in the manuscript revision. The authors also declare no competing financial interests. Dr. Nicholas Pintori gratefully acknowledges the Fondazione Zardi-Gori for the
postdoctoral fellowship within the Zardi-Gori 2020 call in the field of
drug addiction and comorbid diseases.

**Funding** Open access funding provided by Università degli Studi di Cagliari within the CRUI-CARE Agreement. This research has been funded by the Drug Policies Department, Presidency of the Council of Ministers, Italy (projects: “INSIDE-018” and “Effects of NPS: development of a multicentre research for the information enhancement of the Early Warning System”) to M.A.D.L., and RAS-FSC 2018 (Codice intervento: RC_CRP_034; CUP RASSR03071; project: “Multidisciplinary preclinical study on NPS and evaluation of their behavioral and neurophysiological effects related to age and sex”) to M.A.D.L.

Declarations

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Angoa-Pérez M, Kane MJ, Briggs DI et al (2013) Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem 125:102–110. https://doi.org/10.1111/jnc.12114

Araque A, Carmignoto G, Haydon PG et al (2014) Gliotransmitters travel in time and space. Neuron 81:728–739. https://doi.org/10.1016/j.neuron.2014.02.007

Atwood BK, Huffman J, Straiker A, MacKie K (2010) JWH018, a common constituent of “Spice” herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br J Pharmacol 160:585–593. https://doi.org/10.1111/j.1476-5381.2009.00582.x

Bayazit H, Selek S, Karababa IF et al (2017) Evaluation of oxidant/antioxidant status and cytokine levels in patients with cannabis use disorder. Clin Psychopharmacol Neurosci 15:237–242. https://doi.org/10.9758/cpn.2017.15.3.237

Becker MP, Collins PF, Schultz A et al (2018) Longitudinal changes in cognition in young adult cannabis users. J Clin Exp Neuropsychol 40:529–543. https://doi.org/10.1080/13803395.2017.1385729

Bhatt HK, Song D, Musgrave G, Rao PSS (2021) Cannabinoid-induced changes in the immune system: the role of microRNAs. Int Immunopharmacol 98:107832. https://doi.org/10.1016/j.intimp.2021.107832

Bisogno T, Di Marzo V (2010) Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 9(5):564–573. https://doi.org/10.2174/187152710793361568

Bortolato M, Godar SC, Davarian S, Chen K, Shih JC (2009) Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice. Neuropsychopharmacology 34(13):2746–2757. https://doi.org/10.1038/npp.2009.118

Castelli MP, Madeddu C, Casti A et al (2014) Δ9-Tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity. PLoS ONE 9:1–11. https://doi.org/10.1371/journal.pone.0098079

Cha HJ, Seong YH, Song MJ et al (2015) Neurotoxicity of synthetic cannabinoids JWH-081 and JWH-210. Biomol Ther 23:597–603. https://doi.org/10.4062/biomolther.2015.057

Chambers RA, Taylor JR, Potenza MN (2003) Developmental neurocuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 160:1041–1052. https://doi.org/10.1176/appi.ajp.160.6.1041

Claus ED, Feldstein Ewing SW, Magnan RE, Montanaro E, Hutchison KE, Bryan AD (2018) Neural mechanisms of risky decision making in adolescents reporting frequent alcohol and/or marijuana use. Brain Imaging Behav 12:564–576. https://doi.org/10.1007/s11682-017-9723-x

Clayton HB, Lowry R, Ashley C et al (2017) Health risk behaviors with synthetic cannabinoids versus Marijuana. Pediatrics 139:e20162675. https://doi.org/10.1542/peds.2016-2675

Cohen K, Weinstein AM (2018) Synthetic and non-synthetic cannabinoid drugs and their adverse effects-a review from public health prospective. Front Public Health 6:13–16. https://doi.org/10.3389/fpubh.2018.00162

Coller JK, Hutchinson MR (2012) Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol Ther 134:219–245. https://doi.org/10.1016/j.pharmthera.2012.01.008

Crews FT, Zou J, Qin L (2011) Induction of innate immune genes in brain create the neurobiology of addiction. Brain Behav Immun 25:S4–S12. https://doi.org/10.1016/j.bbi.2011.03.003

Cutando L, Busquets-Garcia A, Puighermanal E et al (2013) Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. J Clin Invest 123:2816–2831. https://doi.org/10.1172/JCI67569

da Rocha FF, Correa H, Teixeira AL (2008) Obsessive-compulsive disorder and immunology: a review. Prog Neuropsychopharmacol Biol Psychiatry. 32(5):1139–46. https://doi.org/10.1016/j.pnpbp.2007.12.026

de Brouwer G, Fick A, Harvey BH, Wolmarans W (2019) A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive-compulsive disorder: Mapping the way forward. Cogn Affect Behav Neurosci 19:1–39. https://doi.org/10.3758/s13415-018-00653-4

De Luca MA, Valentini V, Bimpisidis Z et al (2014) Endocannabinoid 2-arachidonoylglycerol self-administration by Sprague-Dawley rats and stimulation of in vivo dopamine transmission in the nucleus accumbens shell. Front Psychiatry 5:1–9. https://doi.org/10.3389/fpsyt.2014.00140

De Luca MA, Bimpisidis Z, Melis M et al (2015) Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. Neuropharmacology 99:705–714. https://doi.org/10.1016/j.neuropharm.2015.08.041

De Luca MA, Castelli MP, Loi B et al (2016) Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. Neuropharmacology 105:630–638. https://doi.org/10.1016/j.neuropharm.2015.11.017

Di Chiara G (2002) Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 137:75–114. https://doi.org/10.1016/S0166-4328(02)00286-3
Di Chiara G, Bassareo V, Fenu S et al (2004) Dopamine and drug addiction: the nucleus accumbens shell connection. *Neuropharmacology* 47:227–241. https://doi.org/10.1016/j.neuropharm.2004.06.032

Ellgren M, Spano SM, Hurd YL (2007) Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. *Neuropsychopharmacology* 32:607–615. https://doi.org/10.1038/sj.npp.1301127

EMCDDA (2019) European drug report 2019: trends and developments, European Monitoring Centre for Drugs and Drug Addiction. European Union Publications Office, Luxembourg

Festucci F, Buccheri C, Parvopassu A, Oggiano M, Bortolato M, Laviola G, Curcio G, Adriani W (2021) “Himalayan Bridge”: a new unstable suspended bridge to investigate rodents’ venturesome behavior. *Front Behav Neurosci* 15:637074. https://doi.org/10.3389/fnbeh.2021.637074

Fields JA, Swinton MK, Montilla-Perez P, Ricciardelli E, Telese F (2020) The cannabinoid receptor agonist, WIN, suppresses the activation of proinflammatory genes induced by interleukin 1 beta in human astrocytes. *Cannabis Cannabinoid Res*. https://doi.org/10.1089/can.2020.0128

Fishbein-kaminietsky M, Gafni M, Sarne Y (2014) Ultralow Doses of Cannabinoid Drugs Protect the Mouse Brain from Inflammation-Induced Cognitive Damage. *J Neurosci Res* 1677:1669–1677. https://doi.org/10.1002/jnr.23452

Franke H (1995) Influence of chronic alcohol treatment on the GFAP-immunoreactivity in astrocytes of the hippocampus in rats. *Acta Histochem* 97:263–271. https://doi.org/10.1016/S0065-1281(11)80187-X

Frau R, Bini V, Soggiu A, Scheggi S, Pardu A, Fanni S, Roncada P, Puligheddu M, Marrosu F, Caruso D, Devoto P, Bortolato M (2017) The neurosteroidogenic enzyme 5α-reductase mediates psychotic-like complications of sleep deprivation. *Neuropsychopharmacology* 42(11):2196–2205. https://doi.org/10.1038/npp.2017.13

Frau R, Miczán V, Traccis F, Aroni S, Pongor CI, Saba P, Serra V, Sagheddu C, Fanni S, Congiu M, Devoto P, Cheer JF, Katona I, Melis M (2019) Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone. *Nat Neurosci* 22(12):1975–1985. https://doi.org/10.1038/s41593-019-0512-2

Gabaglio M, Zamberletti E, Manenti C et al (2021) Long-term consequences of adolescent exposure to thc-rich/cbd-poor and cbd-rich/thc-poor combinations: a comparison with pure thc treatment in female rats. *Int J Mol Sci* 22:8899. https://doi.org/10.3390/ijms2168899

Gilman JM, Calderon V, Curran MT (2015) Evins AE (2014) Young adult cannabis users report greater propensity for risk-taking only in non-monetary domains. *Drug Alcohol Depend* 147:26–31. https://doi.org/10.1016/j.drugalcdep.2014.12.020

Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience* 77:299–318

Goodman J, Packard MG (2015) The memory system engaged during acquisition determines the effectiveness of different extinction protocols. *Front Behav Neurosci* 9:314. https://doi.org/10.3389/fnbeh.2015.00314

Greer JM, Capecchi MR (2002) Hoxb8 is required for normal grooming behavior in mice. *Neuron* 33:23–34. https://doi.org/10.1016/S0896-6273(01)00564-5

Higuera-Matas A, Miguéns M, Coria SM et al (2012) Sex-specific disturbances of the glutamate/GABA balance in the hippocampus of adult rats subjected to adolescent cannabinoid exposure. *Neuropsycharmacology* 62:1975–1984. https://doi.org/10.1016/j.neuropharm.2011.12.028

Hilário M, Clouse E, Yin H, Costa R (2007) Endocannabinoid signaling is critical for habit formation. *Front Integr Neurosci* 1:6. https://doi.org/10.3389/neuro.07.006.2007

Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D (2014) Trajectory of adolescent cannabis use on addiction vulnerability. *Neuropsycharmacology* 76:416–424. https://doi.org/10.1016/j.neuropharm.2013.07.028

Jacobus J, Bava S, Cohen-Zion M et al (2009) Functional consequences of marijuana use in adolescents. *Pharmacol Biochem Behav* 92:559–565. https://doi.org/10.1016/j.pbb.2009.04.001

Justinova Z, Goldberg SR, Heishman SJ, Tanda G (2005) Self-administration of cannabinoids by experimental animals and human marijuana smokers. *Pharmacol Biochem Behav* 81:285–299. https://doi.org/10.1016/j.pbb.2005.01.026

Kevin RC, Wood KE, Stuart J et al (2017) Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. *J Psychopharmacol* 31:757–769. https://doi.org/10.1177/026981116684336

Kim R, Healey KL, Sepulveda-Orengo MT, Reissner KJ (2018) Astroglial correlates of neuropsychiatric disease: from astrocytopathy to astrogliosis. *Prog Neuro-Psychopharmacology Biol Psychiatry* 87:126–146. https://doi.org/10.1016/j.pnpbp.2017.10.002

Koob GF, Volkow ND (2010) Erratum: Neurocircuitry of addiction (Neuropsychopharmacology (2010) 35 (217–238) https://doi.org/10.1038/npp.2009.110). *Neuropsychopharmacology* 35:1051. https://doi.org/10.1038/npp.2010.4

Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. *Am J Psychiatry* 157:683–694. https://doi.org/10.1176/appi.ajp.157.5.683

Lacagnina MJ, Rivera PD, Bilbo SD (2017) Glial and neuroimmune mechanisms as critical modulators of drug use and abuse. *Neuropsychopharmacology* 42:156–177. https://doi.org/10.1038/npp.2016.121

Lane SD, Cherek DR, Lieving LM, Tcheremissine OV (2005) Marijuana effects on human forgetting functions. *J Exp Anal Behav* 83:67–83. https://doi.org/10.1901/jeab.2005.22-04

Linker KE, Cross SJ, Leslie FM (2018) Glial mechanisms underlying substance use disorders. *Eur J Neurosci* 1–16. https://doi.org/10.1111/ejn.14163

López-Gallardo M, López-Rodríguez AB, Llorente-Berzal Á et al (2012) Maternal deprivation and adolescent cannabinoid exposure impact hippocampal astrocytes, CB1 receptors and brain-derived neurotrophic factor in a sexually dimorphic fashion. *Neuroscience* 204:90–103. https://doi.org/10.1016/j.neuroscience.2011.09.063

Lopez-Rodríguez AB, Llorente-Berzal A, García-Segura LM, Viveros MP (2014) Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats. *Br J Pharmacol* 171:1435–1447. https://doi.org/10.1111/bph.12519

Manitt C, Labelle-Dumais C, Eng C et al (2010) Peri-pubertal emergence of UNC-5 homologue expression by dopamine neurons in rodents. *PLoS ONE* 5:e11463. https://doi.org/10.1371/journal.pone.0011463

Martellotta MC, Cossu G, Fattore L et al (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212–2 in drug-naïve mice. *Neuroscience* 85:327–330. https://doi.org/10.1016/S0306-4522(98)00052-9

McDonald J, Schleifer L, Richards JB, De Wit H (2003) Effects of THC on behavioral measures of impulsivity in humans. *Neuropsychopharmacology* 28:1356–1365. https://doi.org/10.1038/sj.npp.1300176

Mendizábal V, Zimmer A, Maldonado R (2006) Involvement of kappa/dynorphin system in WIN 55,212–2 self-administration in mice.
Neuropsychopharmacology 31(9):1957–1966. https://doi.org/10.1038/sj.npp.1300957

Mensen VT, Vreeker A, Nordgren J, Atkinson A, de la Torre R, Farré M, Ramaekers JG, Brunt TM (2019) Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. Psychopharmacology (Berl) 236(9):2677–2685. https://doi.org/10.1007/s00213-019-05238-8

Meyer HC, Lee FS, Gee DG (2018) The role of the endocannabinoid system and genetic variation in adolescent brain development. Neuropsychopharmacology 43:21–23. https://doi.org/10.1038/npp.2017.143

Miguel-Hidalgo JJ (2005) Lower packing density of glial fibrillary acidic protein–immunoreactive astrocytes in the prelimbic cortex of alcohol-naïve and alcohol-drinking alcohol-preferring rats as compared with alcohol-nonpreferring and Wistar rats. Alcohol Clin Exp Res 29:766–772. https://doi.org/10.1097/01.ALC.0000164378.92680.FA

Miguel-Hidalgo JJ (2009) The role of glial cells in drug abuse. Curr Drug Abuse Rev 2:72–82. https://doi.org/10.2174/1874473710902010076

Miliano C, Margiani G, Fattore L, De Luca MA (2018) Sales and advertising channels of new psychoactive substances (NPS): Internet, social networks, and smartphone apps. Brain Sci 8:123. https://doi.org/10.3390/brainsci8070123

Murphy M, Mills S, Winstone J et al (2017) Chronic adolescent Δ9-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabinoid treatment. Cannabis Cannabinoid Res 2:235–246. https://doi.org/10.1089/can.2017.0034

Musa A, Simola N, Piras G et al (2020) Neurochemical and behavioral characterization after acute and repeated exposure to novel synthetic cannabinoid agonist 5-mdmb-pica. Brain Sci 10:1–14. https://doi.org/10.3390/brainsci10121011

Namba MD, Kupchik YM, Spencer SM et al (2020) Accumbens neuroimmune signaling and dysregulation of astrocytic glutamate transport underlie conditioned nicotine-seeking behavior. Addict Biol 25:e12797. https://doi.org/10.1111/adb.12797

Naneix F, Marchand AR, Di Scala G et al (2012) Parallel maturation of goal-directed behavior and dopaminergic systems during adolescence. J Neurosci 32:16223–16232. https://doi.org/10.1523/JNEUROSCI.3080-12.2012

Navarro M, Carrera MR, Fratta W et al (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21:5344–5350. https://doi.org/10.1523/JNEUROSCI.21/14/5344[pii]

Ninnemann AL, Choi HJ, Stuart GL, Temple JR (2017) Longitudinal predictors of synthetic cannabinoid use in adolescents. Pediatrics 139:e20163009. https://doi.org/10.1542/peds.2016-3009

O'Donnell BF, Skosnik PD, Hetrick WP, Fridberg DJ (2021) Decision making and impulsivity in young adult cannabis users. Front Psychol. 12:679904. https://doi.org/10.3389/fpsyg.2021.679904

Pacifici R, Zuccaro P, Farré M et al (2002) Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 965:421–433. https://doi.org/10.1111/j.1749-6632.2002.tb04183.x

Pacifici R, Zuccaro P, Pichini S et al (2003) Modulation of the immune system in cannabis users. JAMA 289:1929–1931. https://doi.org/10.1001/jama.289.15.1929-a

Pacifici R, Zuccaro P, Farré M et al (2007) Combined immunomodulating properties of 3,4-methylenedioxymethamphetamine (MDMA) and cannabis in humans. Addiction 102:931–936. https://doi.org/10.1111/j.1360-0443.2007.01805.x

Palamar JJ, Barratt MJ, Coney L, Martins SS (2017) Synthetic cannabinoid use among high school seniors. Pediatrics. https://doi.org/10.1542/peds.2017-1330

Parsons LH, Hurd YL (2015) Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci 16:579–94. https://doi.org/10.1038/nrn4004

Paule MG, Allen RR, Bailey JR et al (1992) Chronic marijuana smoke exposure in the rhesus monkey. II: Effects on progressive ratio and conditioned position responding. J Pharmacol Exp Ther 260:210–222

Pekny M, Pekna M, Messing A et al (2016) Astrocytes: a central element in neurological diseases. Acta Neuropathol 131:323–345. https://doi.org/10.1007/s00401-015-1513-1

Pintori N, Loi B, Mereu M (2017) Synthetic cannabinoids: the hidden side of Spice drugs. Behav Pharmacol 28:409–419. https://doi.org/10.1097/FBP.0000000000000323

Pintori N, Castelli MP, Miliano C et al (2021) Repeated exposure to JWH-018 induces adaptive changes in the mesolimbic and mesocortical dopaminergic pathways, glial cells alterations, and behavioural correlates. Br J Pharmacol 178:3476–3497. https://doi.org/10.1111/bph.15494

Pocock JM, Kettenmann H (2007) Neurotransmitter receptors on microglia. Trends Neurosci 30:527–535. https://doi.org/10.1016/j.tins.2007.07.007

Ransohoff RM, Brown MA (2012) Innate immunity in the central nervous system Find the latest version : review series Innate immunity in the central nervous system. J Clin Invest 122:1164–1171. https://doi.org/10.1172/JCI58644.1164

Rao PSS, Bell RL, Engleman EA, Sari Y (2015) Targeting glutamate uptake to treat alcohol use disorders. Front Neurosci 9:144. https://doi.org/10.3389/fnins.2015.00144

Rintala J, Jaatinen P, Kiianmaa K et al (2001) Dose-dependent decrease in glial fibrillary acidic protein-immunoreactivity in rat cerebellum after lifelong ethanol consumption. Alcohol 23:1–8. https://doi.org/10.1016/S0741-8329(00)00116-6

Robson MJ, Turner RC, Naser ZJ et al (2013) SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. Exp Neurol 247:134–142. https://doi.org/10.1016/j.expneurol.2013.04.009

Rubino T, Vigano D, Realini N et al (2008) Chronic Δ9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33:2760–2771. https://doi.org/10.1038/sj.npp.1301664

Salter MW, Beggs S (2014) Sublime microglia: expanding roles for the guardians of the CNS. Cell 158:15–24. https://doi.org/10.1016/j.cell.2014.06.008

Schneider M (2013) Adolescence as a vulnerable period to alter rodent behavior. Cell Tissue Res 354:99–106. https://doi.org/10.1007/s00441-013-1581-2

Smith ACW, Scofield MD, Kalivas PW (2015) The tetrapartite synapse: extracellular matrix remodeling contributes to cortico-coaccumbens plasticity underlying drug addiction. Brain Res 1628:29–39. https://doi.org/10.1016/j.brainres.2015.03.027

Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, Pesa N, Lubman DI, Yücel M (2012) Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology 219(2):575–586. https://doi.org/10.1007/s00213-011-2486-y

Spear LP (2016) Consequences of adolescent use of alcohol and other drugs: studies using rodent models. Neurosci Biobehav Rev 70:228–243. https://doi.org/10.1016/j.neubiorev.2016.07.026

Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017–1030. https://doi.org/10.1002/glia.20983

Suárez I, Bodega G, Ramos JA et al (2000) Neuronal and astroglial response to pre- and perinatal exposure to delta-9-tetrahydrocannabinol in the rat substantia nigra. Dev Neurosci 22:253–263. https://doi.org/10.1159/000017449
Tahir SK, Trogadis JE, Stevens JK, Zimmerman AM (1992) Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem Cell Biol 70:1159–1173. https://doi.org/10.1139/o92-162

Tanaka M, Sackett S, Zhang Y (2020) Endocannabinoid modulation of microglial phenotypes in neuropathology. Front Neurol 11:87. https://doi.org/10.3389/fneur.2020.00087

Tanda G, Goldberg SR (2003) Cannabinoids: reward, dependence, and underlying neurochemical mechanisms — a review of recent preclinical data. 115–134. https://doi.org/10.1007/s00213-003-1485-z

Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R (2009) Marble burying reflects arepetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 204:361–373. https://doi.org/10.1007/s00213-009-1466-y

Tomiyama K, Funada M (2014) Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death. Toxicol Appl Pharmacol. https://doi.org/10.1016/j.taap.2013.10.028

Valentini V, Piras G, De Luca MA, Perra V, Bordi F, Borsini F, Frau R, Di Chiara G (2013) Evidence for a role of a dopamine/5-HT6 receptor interaction in cocaine reinforcement. Neuropharmacology 65:58–64. https://doi.org/10.1016/j.neuropharm.2012.08.025

Wagner KD, Armenta RF, Roth AM et al (2014) Use of synthetic cathinones and cannabimimetics among injection drug users in San Diego, California. Drug Alcohol Depend 141:99–106. https://doi.org/10.1016/j.drugalcdep.2014.05.007

Wrege J, Schmidt A, Walter A et al (2014) Effects of cannabis on impulsivity: a systematic review of neuroimaging findings. Curr Pharm Des 20(13):2126–2137. https://doi.org/10.2174/13816128113199990428

Wu N, Lu XQ, Yan HT et al (2008) Aquaporin 4 deficiency modulates morphine pharmacological actions. Neurosci Lett 448:221–225. https://doi.org/10.1016/j.neulet.2008.10.065

Zamberletti E, Gabaglio M, Prini P et al (2015) Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats. Eur Neuropsychopharmacol 25:2404–2415. https://doi.org/10.1016/j.euroneuro.2015.09.021

Zamberletti E, Gabaglio M, Grilli M et al (2016) Long-term hippocampal glutamate synapse and astrocyte dysfunctions underlying the altered phenotype induced by adolescent THC treatment in male rats. Pharmacol Res 111:459–470. https://doi.org/10.1016/j.phrs.2016.07.008

Zou J, Crews F (2010) Induction of innate immune gene expression cascades in brain slice cultures by ethanol: key role of NF-κB and proinflammatory cytokines. Alcohol Clin Exp Res 34:777–789. https://doi.org/10.1111/j.1530-0277.2010.01150.x

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.